Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Journal of Psychiatric Research August 1, 2023 Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia-Melo et al.
There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at...